Trial Outcomes & Findings for A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants (NCT NCT06186622)
NCT ID: NCT06186622
Last Updated: 2026-05-22
Results Overview
Recruitment status
COMPLETED
Study phase
PHASE1
Target enrollment
50 participants
Primary outcome timeframe
Day 8 (Cohort 1 only): Pre-dose, 0.5, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 60, and 72h post-dose; Day 105 (Cohort 1 only): Pre-dose, 0.5, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 60, and 72h post-dose
Results posted on
2026-05-22
Participant Flow
Participant milestones
| Measure |
Cohort 1: Oral Drug Dosing With or Without Orforglipron Co-Administration
Participants received single oral doses of the following drugs:
* Day 1: 20 milligram (mg) Simvastatin alone
* Day 2: 0.25 mg Digoxin alone
* Day 7: 20 mg Simvastatin + 600 mg Sodium Bicarbonate
* Day 8: 20 mg Rosuvastatin alone
* Day 10: 1000 mg Acetaminophen alone
* Day 12: 0.2 mg Midazolam alone
* Day 14: 1 mg Orforglipron capsule + 1000 mg Acetaminophen administered 2 hours ±10 minutes after Orforglipron administration (staggered dosing)
* Day 15: 1 mg Orforglipron capsule
* Days 16-97: Participants received Orforglipron capsule orally once daily (QD) for 12 weeks, beginning at 1 mg QD. The dose was escalated every 14 days as follows: 1 mg (Days 16-27), 3 mg (Days 28-41), 6 mg (Days 42-55), 12 mg (Days 56-69), 24 mg (Days 70-83), and 36 mg (Days 84-97).
Participants continued 36 mg Orforglipron QD until Day 110, with co-administration of the following drugs:
* Day 98: 20 mg Simvastatin (simultaneous dosing)
* Day 99: 0.25 mg Digoxin (simultaneous dosing)
* Day 104: 20 mg Simvastatin administered 2 hours ±10 minutes after Orforglipron administration (staggered dosing)
* Day 105: 20 mg Rosuvastatin (simultaneous dosing)
* Day 107: 1000 mg Acetaminophen administered 2 hours ±10 minutes after Orforglipron administration (staggered dosing)
* Day 109: 0.2 mg Midazolam (simultaneous dosing)
* Day 111: 20 mg Orforglipron tablet + 20 mg Simvastatin (simultaneous dosing)
|
Cohort 2: Oral Drug Dosing With or Without Orforglipron Co-Administration
Participants received single oral doses of the following drugs:
* Day 1: 20 milligram (mg) Simvastatin alone
* Day 2: 0.25 mg Digoxin alone
* Day 7: 20 mg Simvastatin + 600 mg Sodium Bicarbonate
* Day 9: 1 mg Orforglipron capsule
* Days 10-90: Participants received orforglipron capsule orally QD for 12 weeks, beginning at 1 mg QD. The dose was escalated every 14 days as follows: 1 mg (Days 10-22), 3 mg (Days 23-36), 6 mg (Days 37-50), 12 mg (Days 51-64), 24 mg (Days 65-78), and 36 mg (Days 79-90).
Participants continued 36 mg Orforglipron QD until Day 100, with co-administration of the following drugs:
* Day 93: 20 mg Simvastatin (simultaneous dosing)
* Day 94: 0.25 mg Digoxin (simultaneous dosing)
* Day 99: 20 mg Simvastatin administered 2 hours ±10 minutes after Orforglipron administration (staggered dosing)
* Day 101: 20 mg Orforglipron tablet + 20 mg Simvastatin (simultaneous dosing)
|
|---|---|---|
|
Overall Study
STARTED
|
30
|
20
|
|
Overall Study
Safety Analysis Population (Received at Least One Dose of Study Drug)
|
30
|
20
|
|
Overall Study
COMPLETED
|
22
|
16
|
|
Overall Study
NOT COMPLETED
|
8
|
4
|
Reasons for withdrawal
| Measure |
Cohort 1: Oral Drug Dosing With or Without Orforglipron Co-Administration
Participants received single oral doses of the following drugs:
* Day 1: 20 milligram (mg) Simvastatin alone
* Day 2: 0.25 mg Digoxin alone
* Day 7: 20 mg Simvastatin + 600 mg Sodium Bicarbonate
* Day 8: 20 mg Rosuvastatin alone
* Day 10: 1000 mg Acetaminophen alone
* Day 12: 0.2 mg Midazolam alone
* Day 14: 1 mg Orforglipron capsule + 1000 mg Acetaminophen administered 2 hours ±10 minutes after Orforglipron administration (staggered dosing)
* Day 15: 1 mg Orforglipron capsule
* Days 16-97: Participants received Orforglipron capsule orally once daily (QD) for 12 weeks, beginning at 1 mg QD. The dose was escalated every 14 days as follows: 1 mg (Days 16-27), 3 mg (Days 28-41), 6 mg (Days 42-55), 12 mg (Days 56-69), 24 mg (Days 70-83), and 36 mg (Days 84-97).
Participants continued 36 mg Orforglipron QD until Day 110, with co-administration of the following drugs:
* Day 98: 20 mg Simvastatin (simultaneous dosing)
* Day 99: 0.25 mg Digoxin (simultaneous dosing)
* Day 104: 20 mg Simvastatin administered 2 hours ±10 minutes after Orforglipron administration (staggered dosing)
* Day 105: 20 mg Rosuvastatin (simultaneous dosing)
* Day 107: 1000 mg Acetaminophen administered 2 hours ±10 minutes after Orforglipron administration (staggered dosing)
* Day 109: 0.2 mg Midazolam (simultaneous dosing)
* Day 111: 20 mg Orforglipron tablet + 20 mg Simvastatin (simultaneous dosing)
|
Cohort 2: Oral Drug Dosing With or Without Orforglipron Co-Administration
Participants received single oral doses of the following drugs:
* Day 1: 20 milligram (mg) Simvastatin alone
* Day 2: 0.25 mg Digoxin alone
* Day 7: 20 mg Simvastatin + 600 mg Sodium Bicarbonate
* Day 9: 1 mg Orforglipron capsule
* Days 10-90: Participants received orforglipron capsule orally QD for 12 weeks, beginning at 1 mg QD. The dose was escalated every 14 days as follows: 1 mg (Days 10-22), 3 mg (Days 23-36), 6 mg (Days 37-50), 12 mg (Days 51-64), 24 mg (Days 65-78), and 36 mg (Days 79-90).
Participants continued 36 mg Orforglipron QD until Day 100, with co-administration of the following drugs:
* Day 93: 20 mg Simvastatin (simultaneous dosing)
* Day 94: 0.25 mg Digoxin (simultaneous dosing)
* Day 99: 20 mg Simvastatin administered 2 hours ±10 minutes after Orforglipron administration (staggered dosing)
* Day 101: 20 mg Orforglipron tablet + 20 mg Simvastatin (simultaneous dosing)
|
|---|---|---|
|
Overall Study
Adverse Event
|
6
|
1
|
|
Overall Study
Sponsor Decision
|
0
|
2
|
|
Overall Study
Protocol Violation
|
1
|
0
|
|
Overall Study
Withdrawal by Subject
|
1
|
1
|
Baseline Characteristics
A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants
Baseline characteristics by cohort
| Measure |
Cohort 1: Oral Drug Dosing With or Without Orforglipron
n=30 Participants
Participants received single oral doses of the following drugs:
* Day 1: 20 milligram (mg) Simvastatin alone
* Day 2: 0.25 mg Digoxin alone
* Day 7: 20 mg Simvastatin + 600 mg Sodium Bicarbonate
* Day 8: 20 mg Rosuvastatin alone
* Day 10: 1000 mg Acetaminophen alone
* Day 12: 0.2 mg Midazolam alone
* Day 14: 1 mg Orforglipron capsule + 1000 mg Acetaminophen administered 2 hours ±10 minutes after Orforglipron administration (staggered dosing)
* Day 15: 1 mg Orforglipron capsule
* Days 16-97: Participants received Orforglipron capsule orally once daily (QD) for 12 weeks, beginning at 1 mg QD. The dose was escalated every 14 days as follows: 1 mg (Days 16-27), 3 mg (Days 28-41), 6 mg (Days 42-55), 12 mg (Days 56-69), 24 mg (Days 70-83), and 36 mg (Days 84-97).
Participants continued 36 mg Orforglipron QD until Day 110, with co-administration of the following drugs:
* Day 98: 20 mg Simvastatin (simultaneous dosing)
* Day 99: 0.25 mg Digoxin (simultaneous dosing)
* Day 104: 20 mg Simvastatin administered 2 hours ±10 minutes after Orforglipron administration (staggered dosing)
* Day 105: 20 mg Rosuvastatin (simultaneous dosing)
* Day 107: 1000 mg Acetaminophen administered 2 hours ±10 minutes after Orforglipron administration (staggered dosing)
* Day 109: 0.2 mg Midazolam (simultaneous dosing)
* Day 111: 20 mg Orforglipron tablet + 20 mg Simvastatin (simultaneous dosing)
|
Cohort 2: Oral Drug Dosing With or Without Orforglipron
n=20 Participants
Participants received single oral doses of the following drugs:
* Day 1: 20 mg Simvastatin alone
* Day 2: 0.25 mg Digoxin alone
* Day 7: 20 mg Simvastatin + 600 mg Sodium Bicarbonate
* Day 9: 1 mg Orforglipron capsule
* Days 10-90: Participants received Orforglipron capsule orally QD for 12 weeks, beginning at 1 mg QD. The dose was escalated every 14 days as follows: 1 mg (Days 10-22), 3 mg (Days 23-36), 6 mg (Days 37-50), 12 mg (Days 51-64), 24 mg (Days 65-78), and 36 mg (Days 79-90).
Participants continued 36 mg Orforglipron QD until Day 100, with co-administration of the following drugs:
* Day 93: 20 mg Simvastatin (simultaneous dosing)
* Day 94: 0.25 mg Digoxin (simultaneous dosing)
* Day 99: 20 mg Simvastatin administered 2 hours ±10 minutes after Orforglipron administration (staggered dosing)
* Day 101: 20 mg Orforglipron tablet + 20 mg Simvastatin (simultaneous dosing)
|
Total
n=50 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
45.5 Years
STANDARD_DEVIATION 12.80 • n=2 Participants
|
42.9 Years
STANDARD_DEVIATION 12.17 • n=4 Participants
|
44.4 Years
STANDARD_DEVIATION 12.49 • n=6 Participants
|
|
Sex: Female, Male
Female
|
21 Participants
n=2 Participants
|
13 Participants
n=4 Participants
|
34 Participants
n=6 Participants
|
|
Sex: Female, Male
Male
|
9 Participants
n=2 Participants
|
7 Participants
n=4 Participants
|
16 Participants
n=6 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
12 Participants
n=2 Participants
|
7 Participants
n=4 Participants
|
19 Participants
n=6 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
18 Participants
n=2 Participants
|
13 Participants
n=4 Participants
|
31 Participants
n=6 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=2 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=6 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
1 Participants
n=2 Participants
|
1 Participants
n=4 Participants
|
2 Participants
n=6 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=2 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=6 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=2 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=6 Participants
|
|
Race (NIH/OMB)
Black or African American
|
9 Participants
n=2 Participants
|
4 Participants
n=4 Participants
|
13 Participants
n=6 Participants
|
|
Race (NIH/OMB)
White
|
20 Participants
n=2 Participants
|
15 Participants
n=4 Participants
|
35 Participants
n=6 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=2 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=6 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=2 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=6 Participants
|
|
Region of Enrollment
United States
|
30 Participants
n=2 Participants
|
20 Participants
n=4 Participants
|
50 Participants
n=6 Participants
|
PRIMARY outcome
Timeframe: Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours (h) post-dose; Day 98 (Cohort 1) and Day 93 (Cohort 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dosePopulation: All participants who received at least 1 dose of study drug and had evaluable PK data for this specific outcome. As pre-specified in Statistical Analysis Plan, participants were analyzed according to the treatment regimen they received. Data from Cohorts 1 and 2 were combined, and the pooled results are presented for this outcome measure.
AUC \[0-∞\] of simvastatin and its active acid metabolite (simvastatin acid) following simultaneous administration with or without Orforglipron capsule were reported in this outcome measure.
Outcome measures
| Measure |
Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin
n=36 Participants
Participants received simultaneous dosing of 20 mg simvastatin and 20 mg Orforglipron tablet orally on Day 111 (Cohort 1) and Day 101 (Cohort 2).
|
20 mg Simvastatin Alone
n=50 Participants
Participants received single dose of 20 mg simvastatin alone orally on Day 1 (Cohorts 1 and 2).
|
Staggered 36 mg Orforglipron Capsule + 1000 mg Acetaminophen
Participants received staggered dosing of 36 mg single dose of Orforglipron capsule followed by 1000 mg acetaminophen orally on Day 107 (Cohort 1 only).
|
|---|---|---|---|
|
Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC[0-∞]) of Simvastatin and Its Metabolite Simvastatin Acid Following Simultaneous Administration of Orforglipron Capsule Formulation (Cohort 1 and 2)
Simvastatin
|
18.8 Nanogram* hours per milliliter (ng*h/ml)
Geometric Coefficient of Variation 84.3
|
22.1 Nanogram* hours per milliliter (ng*h/ml)
Geometric Coefficient of Variation 79.2
|
—
|
|
Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC[0-∞]) of Simvastatin and Its Metabolite Simvastatin Acid Following Simultaneous Administration of Orforglipron Capsule Formulation (Cohort 1 and 2)
Metabolite- Simvastatin Acid
|
23.3 Nanogram* hours per milliliter (ng*h/ml)
Geometric Coefficient of Variation 74.2
|
13.6 Nanogram* hours per milliliter (ng*h/ml)
Geometric Coefficient of Variation 79.7
|
—
|
PRIMARY outcome
Timeframe: Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 104 (Cohort 1) and Day 99 (Cohort 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dosePopulation: All participants who received at least 1 dose of study drug and had evaluable PK data. As pre-specified in Statistical Analysis Plan, participants were analyzed according to the treatment regimen they received. Data from Cohorts 1 and 2 were combined, and the pooled results are presented for this outcome measure.
AUC \[0-∞\] of simvastatin and its active acid metabolite (simvastatin acid) following staggered administration with or without Orforglipron capsule were reported in this outcome measure. Simvastatin was administered \~2h (±10 min) after Orforglipron capsule administration (Staggered dosing).
Outcome measures
| Measure |
Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin
n=37 Participants
Participants received simultaneous dosing of 20 mg simvastatin and 20 mg Orforglipron tablet orally on Day 111 (Cohort 1) and Day 101 (Cohort 2).
|
20 mg Simvastatin Alone
n=50 Participants
Participants received single dose of 20 mg simvastatin alone orally on Day 1 (Cohorts 1 and 2).
|
Staggered 36 mg Orforglipron Capsule + 1000 mg Acetaminophen
Participants received staggered dosing of 36 mg single dose of Orforglipron capsule followed by 1000 mg acetaminophen orally on Day 107 (Cohort 1 only).
|
|---|---|---|---|
|
PK: AUC [0-∞] of Simvastatin and Its Metabolite Simvastatin Acid Following Staggered Administration of Orforglipron Capsule Formulation (Cohort 1 and 2)
Metabolite- Simvastatin Acid
|
30.2 ng*h/ml
Geometric Coefficient of Variation 70.3
|
13.6 ng*h/ml
Geometric Coefficient of Variation 79.7
|
—
|
|
PK: AUC [0-∞] of Simvastatin and Its Metabolite Simvastatin Acid Following Staggered Administration of Orforglipron Capsule Formulation (Cohort 1 and 2)
Simvastatin
|
20.1 ng*h/ml
Geometric Coefficient of Variation 76.5
|
22.1 ng*h/ml
Geometric Coefficient of Variation 79.2
|
—
|
PRIMARY outcome
Timeframe: Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 7 (Cohort 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dosePopulation: All participants who received at least 1 dose of study drug and had evaluable PK data for this specific outcome. As pre-specified in Statistical Analysis Plan, participants were analyzed according to the treatment regimen they received. Data from Cohorts 1 and 2 were combined, and the pooled results are presented for this outcome measure.
AUC \[0-∞\] of simvastatin and its active acid metabolite (simvastatin acid) following simultaneous administration with or without sodium bicarbonate administration were reported in this outcome measure.
Outcome measures
| Measure |
Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin
n=47 Participants
Participants received simultaneous dosing of 20 mg simvastatin and 20 mg Orforglipron tablet orally on Day 111 (Cohort 1) and Day 101 (Cohort 2).
|
20 mg Simvastatin Alone
n=50 Participants
Participants received single dose of 20 mg simvastatin alone orally on Day 1 (Cohorts 1 and 2).
|
Staggered 36 mg Orforglipron Capsule + 1000 mg Acetaminophen
Participants received staggered dosing of 36 mg single dose of Orforglipron capsule followed by 1000 mg acetaminophen orally on Day 107 (Cohort 1 only).
|
|---|---|---|---|
|
PK: AUC [0-∞] of Simvastatin and Its Metabolite Simvastatin Acid After Sodium Bicarbonate Coadministration (Cohort 1 and 2)
Simvastatin
|
20.3 ng*h/ml
Geometric Coefficient of Variation 82.8
|
22.1 ng*h/ml
Geometric Coefficient of Variation 79.2
|
—
|
|
PK: AUC [0-∞] of Simvastatin and Its Metabolite Simvastatin Acid After Sodium Bicarbonate Coadministration (Cohort 1 and 2)
Metabolite- Simvastatin Acid
|
14.0 ng*h/ml
Geometric Coefficient of Variation 61.3
|
13.6 ng*h/ml
Geometric Coefficient of Variation 79.7
|
—
|
PRIMARY outcome
Timeframe: Day 2 (For Cohort 1 and 2): Pre-dose, 0.5, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, and 120h post-dose ; Day 99 (Cohort 1) and Day 94 (Cohort 2): Pre-dose, 0.5, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, and 120h post-dosePopulation: All participants who received at least 1 dose of study drug and had evaluable PK data for this specific outcome. As pre-specified in Statistical Analysis Plan, participants were analyzed according to the treatment regimen they received. Data from Cohorts 1 and 2 were combined, and the pooled results are presented for this outcome measure.
Outcome measures
| Measure |
Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin
n=37 Participants
Participants received simultaneous dosing of 20 mg simvastatin and 20 mg Orforglipron tablet orally on Day 111 (Cohort 1) and Day 101 (Cohort 2).
|
20 mg Simvastatin Alone
n=50 Participants
Participants received single dose of 20 mg simvastatin alone orally on Day 1 (Cohorts 1 and 2).
|
Staggered 36 mg Orforglipron Capsule + 1000 mg Acetaminophen
Participants received staggered dosing of 36 mg single dose of Orforglipron capsule followed by 1000 mg acetaminophen orally on Day 107 (Cohort 1 only).
|
|---|---|---|---|
|
PK: AUC [0-∞] of Digoxin (Cohort 1 and 2)
|
22.4 ng*h/ml
Geometric Coefficient of Variation 26.5
|
18.8 ng*h/ml
Geometric Coefficient of Variation 21.5
|
—
|
PRIMARY outcome
Timeframe: Day 8 (Cohort 1 only): Pre-dose, 0.5, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 60, and 72h post-dose; Day 105 (Cohort 1 only): Pre-dose, 0.5, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 60, and 72h post-dosePopulation: All participants who received at least 1 dose of study drug and had evaluable PK data.
Outcome measures
| Measure |
Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin
n=21 Participants
Participants received simultaneous dosing of 20 mg simvastatin and 20 mg Orforglipron tablet orally on Day 111 (Cohort 1) and Day 101 (Cohort 2).
|
20 mg Simvastatin Alone
n=27 Participants
Participants received single dose of 20 mg simvastatin alone orally on Day 1 (Cohorts 1 and 2).
|
Staggered 36 mg Orforglipron Capsule + 1000 mg Acetaminophen
Participants received staggered dosing of 36 mg single dose of Orforglipron capsule followed by 1000 mg acetaminophen orally on Day 107 (Cohort 1 only).
|
|---|---|---|---|
|
PK: AUC [0-∞] of Rosuvastatin (Cohort 1 Only)
|
192 ng*h/ml
Geometric Coefficient of Variation 60.1
|
116 ng*h/ml
Geometric Coefficient of Variation 52.1
|
—
|
PRIMARY outcome
Timeframe: Day 10 (Cohort 1 only): Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-dose; Day 14 (Cohort 1 only): Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-dose; Day 107 (Cohort 1 only): Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-dosePopulation: All participants who received at least 1 dose of study drug and had evaluable PK data.
AUC \[0-∞\] of acetaminophen following staggered administration with or without either 1 mg or 36 mg Orforglipron capsule were reported in this outcome measure. Acetaminophen was administered \~2h (±10 min) after Orforglipron capsule administration (Staggered dosing).
Outcome measures
| Measure |
Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin
n=27 Participants
Participants received simultaneous dosing of 20 mg simvastatin and 20 mg Orforglipron tablet orally on Day 111 (Cohort 1) and Day 101 (Cohort 2).
|
20 mg Simvastatin Alone
n=27 Participants
Participants received single dose of 20 mg simvastatin alone orally on Day 1 (Cohorts 1 and 2).
|
Staggered 36 mg Orforglipron Capsule + 1000 mg Acetaminophen
n=22 Participants
Participants received staggered dosing of 36 mg single dose of Orforglipron capsule followed by 1000 mg acetaminophen orally on Day 107 (Cohort 1 only).
|
|---|---|---|---|
|
PK: AUC [0-∞] of Acetaminophen (Cohort 1 Only)
|
52900 ng*h/ml
Geometric Coefficient of Variation 39.0
|
59900 ng*h/ml
Geometric Coefficient of Variation 37.2
|
73000 ng*h/ml
Geometric Coefficient of Variation 64.3
|
PRIMARY outcome
Timeframe: Day 12 (Cohort 1 only): Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, and 24h post-dose; Day 109 (Cohort 1 only): Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, and 24h post-dosePopulation: All participants who received at least 1 dose of study drug and had evaluable PK data.
AUC \[0-∞\] of midazolam and its metabolite (1'-Hydroxymidazolam) following simultaneous administration with or without Orforglipron capsule were reported in this outcome measure.
Outcome measures
| Measure |
Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin
n=21 Participants
Participants received simultaneous dosing of 20 mg simvastatin and 20 mg Orforglipron tablet orally on Day 111 (Cohort 1) and Day 101 (Cohort 2).
|
20 mg Simvastatin Alone
n=27 Participants
Participants received single dose of 20 mg simvastatin alone orally on Day 1 (Cohorts 1 and 2).
|
Staggered 36 mg Orforglipron Capsule + 1000 mg Acetaminophen
Participants received staggered dosing of 36 mg single dose of Orforglipron capsule followed by 1000 mg acetaminophen orally on Day 107 (Cohort 1 only).
|
|---|---|---|---|
|
PK: AUC [0-∞] of Midazolam and Its Metabolite 1'-Hydroxymidazolam (Cohort 1 Only)
Midazolam
|
4.60 ng*h/ml
Geometric Coefficient of Variation 47.3
|
3.82 ng*h/ml
Geometric Coefficient of Variation 41.2
|
—
|
|
PK: AUC [0-∞] of Midazolam and Its Metabolite 1'-Hydroxymidazolam (Cohort 1 Only)
Metabolite- 1'-Hydroxymidazolam
|
1.34 ng*h/ml
Geometric Coefficient of Variation 48.5
|
1.00 ng*h/ml
Geometric Coefficient of Variation 43.2
|
—
|
PRIMARY outcome
Timeframe: Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 98 (Cohort 1) and Day 93 (Cohort 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dosePopulation: All participants who received at least 1 dose of study drug and had evaluable PK data. As pre-specified in Statistical Analysis Plan, participants were analyzed according to the treatment regimen they received. Data from Cohorts 1 and 2 were combined, and the pooled results are presented for this outcome measure.
Cmax of simvastatin and its active acid metabolite (simvastatin acid) following simultaneous administration with or without Orforglipron capsule were reported in this outcome measure.
Outcome measures
| Measure |
Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin
n=37 Participants
Participants received simultaneous dosing of 20 mg simvastatin and 20 mg Orforglipron tablet orally on Day 111 (Cohort 1) and Day 101 (Cohort 2).
|
20 mg Simvastatin Alone
n=50 Participants
Participants received single dose of 20 mg simvastatin alone orally on Day 1 (Cohorts 1 and 2).
|
Staggered 36 mg Orforglipron Capsule + 1000 mg Acetaminophen
Participants received staggered dosing of 36 mg single dose of Orforglipron capsule followed by 1000 mg acetaminophen orally on Day 107 (Cohort 1 only).
|
|---|---|---|---|
|
PK: Maximum Observed Concentration (Cmax) of Simvastatin and Its Metabolite Simvastatin Acid Following Simultaneous Administration of Orforglipron Capsule Formulation (Cohort 1 and 2)
Simvastatin
|
4.07 Nanogram per milliliter (ng/ml)
Geometric Coefficient of Variation 89.1
|
4.68 Nanogram per milliliter (ng/ml)
Geometric Coefficient of Variation 80.3
|
—
|
|
PK: Maximum Observed Concentration (Cmax) of Simvastatin and Its Metabolite Simvastatin Acid Following Simultaneous Administration of Orforglipron Capsule Formulation (Cohort 1 and 2)
Metabolite-Simvastatin Acid
|
2.72 Nanogram per milliliter (ng/ml)
Geometric Coefficient of Variation 84.8
|
1.25 Nanogram per milliliter (ng/ml)
Geometric Coefficient of Variation 74.6
|
—
|
PRIMARY outcome
Timeframe: Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 104 (Cohort 1) and Day 99 (Cohort 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dosePopulation: All participants who received at least 1 dose of study drug and had evaluable PK data. As pre-specified in Statistical Analysis Plan, participants were analyzed according to the treatment regimen they received. Data from Cohorts 1 and 2 were combined, and the pooled results are presented for this outcome measure.
Cmax of simvastatin and its active acid metabolite (simvastatin acid) following staggered administration with or without Orforglipron capsule were reported in this outcome measure. Simvastatin was administered \~2h (±10 min) after Orforglipron capsule administration (Staggered dosing).
Outcome measures
| Measure |
Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin
n=37 Participants
Participants received simultaneous dosing of 20 mg simvastatin and 20 mg Orforglipron tablet orally on Day 111 (Cohort 1) and Day 101 (Cohort 2).
|
20 mg Simvastatin Alone
n=50 Participants
Participants received single dose of 20 mg simvastatin alone orally on Day 1 (Cohorts 1 and 2).
|
Staggered 36 mg Orforglipron Capsule + 1000 mg Acetaminophen
Participants received staggered dosing of 36 mg single dose of Orforglipron capsule followed by 1000 mg acetaminophen orally on Day 107 (Cohort 1 only).
|
|---|---|---|---|
|
PK: Cmax of Simvastatin and Its Metabolite Simvastatin Acid Following Staggered Administration of Orforglipron Capsule Formulation (Cohort 1 and 2)
Simvastatin
|
3.34 ng/ml
Geometric Coefficient of Variation 82.7
|
4.68 ng/ml
Geometric Coefficient of Variation 80.3
|
—
|
|
PK: Cmax of Simvastatin and Its Metabolite Simvastatin Acid Following Staggered Administration of Orforglipron Capsule Formulation (Cohort 1 and 2)
Metabolite- Simvastatin Acid
|
2.94 ng/ml
Geometric Coefficient of Variation 70.2
|
1.25 ng/ml
Geometric Coefficient of Variation 74.6
|
—
|
PRIMARY outcome
Timeframe: Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 7 (Cohort 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dosePopulation: All participants who received at least 1 dose of study drug and had evaluable PK data. As pre-specified in Statistical Analysis Plan, participants were analyzed according to the treatment regimen they received. Data from Cohorts 1 and 2 were combined, and the pooled results are presented for this outcome measure.
Cmax of simvastatin and its active acid metabolite (simvastatin acid) following simultaneous administration with or without sodium bicarbonate administration were reported in this outcome measure.
Outcome measures
| Measure |
Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin
n=50 Participants
Participants received simultaneous dosing of 20 mg simvastatin and 20 mg Orforglipron tablet orally on Day 111 (Cohort 1) and Day 101 (Cohort 2).
|
20 mg Simvastatin Alone
n=50 Participants
Participants received single dose of 20 mg simvastatin alone orally on Day 1 (Cohorts 1 and 2).
|
Staggered 36 mg Orforglipron Capsule + 1000 mg Acetaminophen
Participants received staggered dosing of 36 mg single dose of Orforglipron capsule followed by 1000 mg acetaminophen orally on Day 107 (Cohort 1 only).
|
|---|---|---|---|
|
PK: Cmax of Simvastatin and Its Metabolite Simvastatin Acid After Sodium Bicarbonate Coadministration (Cohort 1 and 2)
Simvastatin
|
4.62 ng/ml
Geometric Coefficient of Variation 69.0
|
4.68 ng/ml
Geometric Coefficient of Variation 80.3
|
—
|
|
PK: Cmax of Simvastatin and Its Metabolite Simvastatin Acid After Sodium Bicarbonate Coadministration (Cohort 1 and 2)
Metabolite- Simvastatin Acid
|
1.23 ng/ml
Geometric Coefficient of Variation 67.2
|
1.25 ng/ml
Geometric Coefficient of Variation 74.6
|
—
|
PRIMARY outcome
Timeframe: Day 2 (For Cohort 1 and 2): Pre-dose, 0.5, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, and 120h post-dose; Day 99 (Cohort 1) and Day 94 (Cohort 2): Pre-dose, 0.5, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, and 120h post-dosePopulation: All participants who received at least 1 dose of study drug and had evaluable PK data. As pre-specified in Statistical Analysis Plan, participants were analyzed according to the treatment regimen they received. Data from Cohorts 1 and 2 were combined, and the pooled results are presented for this outcome measure.
Outcome measures
| Measure |
Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin
n=37 Participants
Participants received simultaneous dosing of 20 mg simvastatin and 20 mg Orforglipron tablet orally on Day 111 (Cohort 1) and Day 101 (Cohort 2).
|
20 mg Simvastatin Alone
n=50 Participants
Participants received single dose of 20 mg simvastatin alone orally on Day 1 (Cohorts 1 and 2).
|
Staggered 36 mg Orforglipron Capsule + 1000 mg Acetaminophen
Participants received staggered dosing of 36 mg single dose of Orforglipron capsule followed by 1000 mg acetaminophen orally on Day 107 (Cohort 1 only).
|
|---|---|---|---|
|
PK: Cmax of Digoxin (Cohorts 1 and 2)
|
1.20 ng/ml
Geometric Coefficient of Variation 46.1
|
1.02 ng/ml
Geometric Coefficient of Variation 26.1
|
—
|
PRIMARY outcome
Timeframe: Day 8 (Cohort 1 only): Pre-dose, 0.5, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 60, and 72h post-dose; Day 105 (Cohort 1 only): Pre-dose, 0.5, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 60, and 72h post-dosePopulation: All participants who received at least 1 dose of study drug and had evaluable PK data.
Outcome measures
| Measure |
Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin
n=21 Participants
Participants received simultaneous dosing of 20 mg simvastatin and 20 mg Orforglipron tablet orally on Day 111 (Cohort 1) and Day 101 (Cohort 2).
|
20 mg Simvastatin Alone
n=27 Participants
Participants received single dose of 20 mg simvastatin alone orally on Day 1 (Cohorts 1 and 2).
|
Staggered 36 mg Orforglipron Capsule + 1000 mg Acetaminophen
Participants received staggered dosing of 36 mg single dose of Orforglipron capsule followed by 1000 mg acetaminophen orally on Day 107 (Cohort 1 only).
|
|---|---|---|---|
|
PK: Cmax of Rosuvastatin (Cohort 1 Only)
|
14.2 ng/ml
Geometric Coefficient of Variation 83.3
|
11.4 ng/ml
Geometric Coefficient of Variation 69.8
|
—
|
PRIMARY outcome
Timeframe: Day 10 (Cohort 1 only): Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-dose; Day 14 (Cohort 1 only): Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-dose; Day 107 (Cohort 1 only): Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24h post-dosePopulation: All participants who received at least 1 dose of study drug and had evaluable PK data.
Cmax of acetaminophen following staggered administration with or without either 1 mg or 36 mg Orforglipron capsule were reported in this outcome measure. Acetaminophen was administered \~2h (±10 min) after Orforglipron capsule administration (Staggered dosing).
Outcome measures
| Measure |
Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin
n=27 Participants
Participants received simultaneous dosing of 20 mg simvastatin and 20 mg Orforglipron tablet orally on Day 111 (Cohort 1) and Day 101 (Cohort 2).
|
20 mg Simvastatin Alone
n=27 Participants
Participants received single dose of 20 mg simvastatin alone orally on Day 1 (Cohorts 1 and 2).
|
Staggered 36 mg Orforglipron Capsule + 1000 mg Acetaminophen
n=22 Participants
Participants received staggered dosing of 36 mg single dose of Orforglipron capsule followed by 1000 mg acetaminophen orally on Day 107 (Cohort 1 only).
|
|---|---|---|---|
|
PK: Cmax of Acetaminophen (Cohort 1 Only)
|
7760 ng/ml
Geometric Coefficient of Variation 42.2
|
10800 ng/ml
Geometric Coefficient of Variation 29.5
|
10800 ng/ml
Geometric Coefficient of Variation 57.7
|
PRIMARY outcome
Timeframe: Day 12 (Cohort 1 only): Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, and 24h post-dose; Day 109 (Cohort 1 only): Pre-dose, 0.5, 0.75, 1, 2, 3, 4, 6, 9, 12, and 24h post-dosePopulation: All participants who received at least 1 dose of study drug and had evaluable PK data.
Cmax of Midazolam and its metabolite (1'-Hydroxymidazolam) following simultaneous administration with or without Orforglipron capsule is reported in this outcome measure.
Outcome measures
| Measure |
Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin
n=21 Participants
Participants received simultaneous dosing of 20 mg simvastatin and 20 mg Orforglipron tablet orally on Day 111 (Cohort 1) and Day 101 (Cohort 2).
|
20 mg Simvastatin Alone
n=27 Participants
Participants received single dose of 20 mg simvastatin alone orally on Day 1 (Cohorts 1 and 2).
|
Staggered 36 mg Orforglipron Capsule + 1000 mg Acetaminophen
Participants received staggered dosing of 36 mg single dose of Orforglipron capsule followed by 1000 mg acetaminophen orally on Day 107 (Cohort 1 only).
|
|---|---|---|---|
|
PK: Cmax of Midazolam and Its Metabolite 1'-Hydroxymidazolam (Cohort 1 Only)
Midazolam
|
1.33 ng/ml
Geometric Coefficient of Variation 43.8
|
1.23 ng/ml
Geometric Coefficient of Variation 36.1
|
—
|
|
PK: Cmax of Midazolam and Its Metabolite 1'-Hydroxymidazolam (Cohort 1 Only)
Metabolite- 1'-Hydroxymidazolam
|
0.357 ng/ml
Geometric Coefficient of Variation 54.6
|
0.331 ng/ml
Geometric Coefficient of Variation 46.8
|
—
|
SECONDARY outcome
Timeframe: Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 111 (Cohort 1) and Day 101 (Cohort 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dosePopulation: All participants who received at least 1 dose of study drug and had evaluable PK data. As pre-specified in Statistical Analysis Plan, participants were analyzed according to the treatment regimen they received. Data from Cohorts 1 and 2 were combined, and the pooled results are presented for this outcome measure.
AUC \[0-∞\] of simvastatin and its active acid metabolite (simvastatin acid) following simultaneous administration with or without Orforglipron tablet were reported in this outcome measure.
Outcome measures
| Measure |
Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin
n=37 Participants
Participants received simultaneous dosing of 20 mg simvastatin and 20 mg Orforglipron tablet orally on Day 111 (Cohort 1) and Day 101 (Cohort 2).
|
20 mg Simvastatin Alone
n=50 Participants
Participants received single dose of 20 mg simvastatin alone orally on Day 1 (Cohorts 1 and 2).
|
Staggered 36 mg Orforglipron Capsule + 1000 mg Acetaminophen
Participants received staggered dosing of 36 mg single dose of Orforglipron capsule followed by 1000 mg acetaminophen orally on Day 107 (Cohort 1 only).
|
|---|---|---|---|
|
PK: AUC [0-∞] of Simvastatin and Its Metabolite Simvastatin Acid Following Administration of Orforglipron Tablet Formulation (Cohort 1 and 2)
Simvastatin
|
21.0 ng*h/ml
Geometric Coefficient of Variation 82.2
|
22.1 ng*h/ml
Geometric Coefficient of Variation 79.2
|
—
|
|
PK: AUC [0-∞] of Simvastatin and Its Metabolite Simvastatin Acid Following Administration of Orforglipron Tablet Formulation (Cohort 1 and 2)
Metabolite- Simvastatin Acid
|
29.3 ng*h/ml
Geometric Coefficient of Variation 72.0
|
13.6 ng*h/ml
Geometric Coefficient of Variation 79.7
|
—
|
SECONDARY outcome
Timeframe: Day 1 (For Cohorts 1 and 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 h post-dose; Day 111 (Cohort 1) and Day 101 (Cohort 2): Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24h post-dosePopulation: All participants who received at least 1 dose of study drug and had evaluable PK data. As pre-specified in Statistical Analysis Plan, participants were analyzed according to the treatment regimen they received. Data from Cohorts 1 and 2 were combined, and the pooled results are presented for this outcome measure.
Cmax of simvastatin and its active acid metabolite (simvastatin acid) following simultaneous administration with or without Orforglipron tablet were reported in this outcome measure.
Outcome measures
| Measure |
Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin
n=37 Participants
Participants received simultaneous dosing of 20 mg simvastatin and 20 mg Orforglipron tablet orally on Day 111 (Cohort 1) and Day 101 (Cohort 2).
|
20 mg Simvastatin Alone
n=50 Participants
Participants received single dose of 20 mg simvastatin alone orally on Day 1 (Cohorts 1 and 2).
|
Staggered 36 mg Orforglipron Capsule + 1000 mg Acetaminophen
Participants received staggered dosing of 36 mg single dose of Orforglipron capsule followed by 1000 mg acetaminophen orally on Day 107 (Cohort 1 only).
|
|---|---|---|---|
|
PK: Cmax of Simvastatin and Its Metabolite Simvastatin Acid Following Administration of Orforglipron Tablet Formulation (Cohort 1 and 2)
Simvastatin
|
3.78 ng/ml
Geometric Coefficient of Variation 73.6
|
4.68 ng/ml
Geometric Coefficient of Variation 80.3
|
—
|
|
PK: Cmax of Simvastatin and Its Metabolite Simvastatin Acid Following Administration of Orforglipron Tablet Formulation (Cohort 1 and 2)
Metabolite- Simvastatin Acid
|
3.00 ng/ml
Geometric Coefficient of Variation 67.9
|
1.25 ng/ml
Geometric Coefficient of Variation 74.6
|
—
|
Adverse Events
Cohort 1: 6 mg Orforglipron Capsule QD (Day 42 to Day 55)
Serious events: 0 serious events
Other events: 5 other events
Deaths: 0 deaths
Cohort 1: 12 mg Orforglipron Capsule QD (Day 56 to Day 69)
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
Cohort 1: 24 mg Orforglipron Capsule QD (Day 70 to Day 83)
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
Cohort 1: 36 mg Orforglipron Capsule QD (Day 84 to Day 97)
Serious events: 0 serious events
Other events: 11 other events
Deaths: 0 deaths
Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 98)
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 0.25 mg Digoxin (Day 99)
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
Cohort 1: 36 mg Orforglipron Capsule QD (Day 100 to Day 103)
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
Cohort 1: Staggered 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 104)
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 20 mg Rosuvastatin (Day 105)
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
Cohort 1: 36 mg Orforglipron Capsule (Day 106)
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
Cohort 1: Staggered 36 mg Orforglipron Capsule + 1000 mg Acetaminophen (Day 107)
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
Cohort 1: 36 mg Orforglipron Capsule (Day 108)
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 0.2 mg Midazolam (Day 109)
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
Cohort 1: 36 mg Orforglipron Capsule (Day 110)
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Cohort 1: Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin (Day 111)
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
Cohort 2: 20 mg Simvastatin Alone (Day 1)
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
Cohort 2: 0.25 mg Digoxin Alone (Day 2)
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Cohort 2: Simultaneous 20 mg Simvastatin + 600 mg Sodium Bicarbonate (Day 7)
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Cohort 2: 1 mg Orforglipron Capsule QD (Day 9 to Day 22)
Serious events: 0 serious events
Other events: 9 other events
Deaths: 0 deaths
Cohort 2: 3 mg Orforglipron Capsule QD (Day 23 to Day 36)
Serious events: 0 serious events
Other events: 7 other events
Deaths: 0 deaths
Cohort 2: 6 mg Orforglipron Capsule QD (Day 37 to Day 50)
Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths
Cohort 2: 12 mg Orforglipron Capsule QD (Day 51 to Day 64)
Serious events: 1 serious events
Other events: 6 other events
Deaths: 0 deaths
Cohort 2: 24 mg Orforglipron Capsule QD (Day 65 to Day 78)
Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths
Cohort 2: 36 mg Orforglipron Capsule QD (Day 79 to Day 92)
Serious events: 0 serious events
Other events: 10 other events
Deaths: 0 deaths
Cohort 2: Simultaneous 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 93)
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
Cohort 2: Simultaneous 36 mg Orforglipron Capsule + 0.25 mg Digoxin (Day 94)
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
Cohort 2: 36 mg Orforglipron Capsule QD (Day 95 to Day 98)
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
Cohort 2: Staggered 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 99)
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
Cohort 2: 36 mg Orforglipron Capsule (Day 100)
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Cohort 2: Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin (Day 101)
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
Cohort 1: 20 mg Simvastatin Alone (Day 1)
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
Cohort 1: 0.25 mg Digoxin Alone (Day 2)
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Cohort 1: 20 mg Simvastatin + 600 mg Sodium Bicarbonate (Day 7)
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Cohort 1: 20 mg Rosuvastatin Alone (Day 8)
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Cohort 1: 1000 mg Acetaminophen Alone (Day 10)
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
Cohort 1: 0.2 mg Midazolam Alone (Day 12)
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Cohort 1: Staggered 1 mg Orforglipron Capsule + 1000 mg Acetaminophen (Day 14)
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
Cohort 1: 1 mg Orforglipron Capsule QD (Day 15 to Day 27)
Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths
Cohort 1: 3 mg Orforglipron Capsule QD (Day 28 to Day 41)
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
Cohort 1: 6 mg Orforglipron Capsule QD (Day 42 to Day 55)
n=26 participants at risk
Participants received 6 mg Orforglipron capsule once daily from Day 42 through Day 55.
|
Cohort 1: 12 mg Orforglipron Capsule QD (Day 56 to Day 69)
n=26 participants at risk
Participants received 12 mg Orforglipron capsule once daily from Day 56 through Day 69.
|
Cohort 1: 24 mg Orforglipron Capsule QD (Day 70 to Day 83)
n=26 participants at risk
Participants received 24 mg Orforglipron capsule once daily from Day 70 through Day 83.
|
Cohort 1: 36 mg Orforglipron Capsule QD (Day 84 to Day 97)
n=26 participants at risk
Participants received 36 mg Orforglipron capsule once daily from Day 84 through Day 97.
|
Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 98)
n=22 participants at risk
Participants received simultaneous dosing of 20 mg simvastatin and 36 mg Orforglipron orally on Day 98.
|
Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 0.25 mg Digoxin (Day 99)
n=22 participants at risk
Participants received simultaneous dosing of 0.25 mg digoxin and 36 mg Orforglipron orally on Day 99.
|
Cohort 1: 36 mg Orforglipron Capsule QD (Day 100 to Day 103)
n=22 participants at risk
Participants received 36 mg Orforglipron capsule once daily from Day 100 through Day 103.
|
Cohort 1: Staggered 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 104)
n=22 participants at risk
Participants received staggered dosing of 36 mg Orforglipron followed by 20 mg Simvastatin orally on Day 104.
|
Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 20 mg Rosuvastatin (Day 105)
n=22 participants at risk
Participants received simultaneous dosing of 20 mg rosuvastatin and 36 mg Orforglipron orally on Day 105.
|
Cohort 1: 36 mg Orforglipron Capsule (Day 106)
n=22 participants at risk
Participants received 36 mg Orforglipron orally on Day 106.
|
Cohort 1: Staggered 36 mg Orforglipron Capsule + 1000 mg Acetaminophen (Day 107)
n=22 participants at risk
Participants received staggered dosing of 36 mg Orforglipron capsule followed by 1000 mg acetaminophen orally on Day 107.
|
Cohort 1: 36 mg Orforglipron Capsule (Day 108)
n=22 participants at risk
Participants received 36 mg Orforglipron orally on Day 108.
|
Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 0.2 mg Midazolam (Day 109)
n=21 participants at risk
Participants received simultaneous dosing of 0.2 mg midazolam and 36 mg Orforglipron orally on Day 109.
|
Cohort 1: 36 mg Orforglipron Capsule (Day 110)
n=22 participants at risk
Participants received 36 mg Orforglipron orally on Day 110.
|
Cohort 1: Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin (Day 111)
n=22 participants at risk
Participants received simultaneous dosing of 20 mg simvastatin and 20 mg Orforglipron orally on Day 111.
|
Cohort 2: 20 mg Simvastatin Alone (Day 1)
n=20 participants at risk
Participants received single dose of 20 mg simvastatin alone orally on Day 1.
|
Cohort 2: 0.25 mg Digoxin Alone (Day 2)
n=20 participants at risk
Participants received 0.25 mg digoxin alone on Day 2.
|
Cohort 2: Simultaneous 20 mg Simvastatin + 600 mg Sodium Bicarbonate (Day 7)
n=20 participants at risk
Participants received simultaneous dosing of 20 mg simvastatin and 600 mg sodium bicarbonate orally on Day 7.
|
Cohort 2: 1 mg Orforglipron Capsule QD (Day 9 to Day 22)
n=20 participants at risk
Participants received 1 mg Orforglipron capsule once daily from Day 9 through Day 22.
|
Cohort 2: 3 mg Orforglipron Capsule QD (Day 23 to Day 36)
n=20 participants at risk
Participants received 3 mg Orforglipron capsule once daily from Day 23 through Day 36.
|
Cohort 2: 6 mg Orforglipron Capsule QD (Day 37 to Day 50)
n=19 participants at risk
Participants received 6 mg Orforglipron capsule once daily from Day 37 through Day 50.
|
Cohort 2: 12 mg Orforglipron Capsule QD (Day 51 to Day 64)
n=19 participants at risk
Participants received 12 mg Orforglipron capsule once daily from Day 51 through Day 64.
|
Cohort 2: 24 mg Orforglipron Capsule QD (Day 65 to Day 78)
n=18 participants at risk
Participants received 24 mg Orforglipron capsule once daily from Day 65 through Day 78.
|
Cohort 2: 36 mg Orforglipron Capsule QD (Day 79 to Day 92)
n=18 participants at risk
Participants received 36 mg Orforglipron capsule once daily from Day79 through Day 92.
|
Cohort 2: Simultaneous 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 93)
n=16 participants at risk
Participants received simultaneous dosing of 20 mg simvastatin and 36 mg Orforglipron orally on Day 93.
|
Cohort 2: Simultaneous 36 mg Orforglipron Capsule + 0.25 mg Digoxin (Day 94)
n=16 participants at risk
Participants received simultaneous dosing of 0.25 mg digoxin and 36 mg Orforglipron orally on Day 94.
|
Cohort 2: 36 mg Orforglipron Capsule QD (Day 95 to Day 98)
n=16 participants at risk
Participants received 36 mg Orforglipron capsule once daily from Day 95 through Day 98.
|
Cohort 2: Staggered 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 99)
n=16 participants at risk
Participants received staggered dosing of 36 mg Orforglipron followed by 20 mg Simvastatin orally on Day 99.
|
Cohort 2: 36 mg Orforglipron Capsule (Day 100)
n=16 participants at risk
Participants received 36 mg Orforglipron capsule orally on Day 100.
|
Cohort 2: Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin (Day 101)
n=16 participants at risk
Participants received simultaneous dosing of 20 mg simvastatin and 20 mg Orforglipron orally on Day 101.
|
Cohort 1: 20 mg Simvastatin Alone (Day 1)
n=30 participants at risk
Participants received single dose of 20 mg simvastatin alone orally on Day 1.
|
Cohort 1: 0.25 mg Digoxin Alone (Day 2)
n=30 participants at risk
Participants received 0.25 mg digoxin alone on Day 2.
|
Cohort 1: 20 mg Simvastatin + 600 mg Sodium Bicarbonate (Day 7)
n=28 participants at risk
Participants received simultaneous dosing of 20 mg simvastatin and 600 mg sodium bicarbonate orally on Day 7.
|
Cohort 1: 20 mg Rosuvastatin Alone (Day 8)
n=28 participants at risk
Participants received single dose of 20 mg rosuvastatin alone orally on Day 8.
|
Cohort 1: 1000 mg Acetaminophen Alone (Day 10)
n=27 participants at risk
Participants received single dose of 1000 mg acetaminophen alone orally on Day 10.
|
Cohort 1: 0.2 mg Midazolam Alone (Day 12)
n=27 participants at risk
Participants received single dose of 0.2 mg midazolam alone orally on Day 12.
|
Cohort 1: Staggered 1 mg Orforglipron Capsule + 1000 mg Acetaminophen (Day 14)
n=27 participants at risk
Participants received staggered dosing of 1 mg single dose of Orforglipron followed by 1000 mg acetaminophen orally on Day 14.
|
Cohort 1: 1 mg Orforglipron Capsule QD (Day 15 to Day 27)
n=27 participants at risk
Participants received 1 mg Orforglipron capsule once daily from Day 15 through Day 27.
|
Cohort 1: 3 mg Orforglipron Capsule QD (Day 28 to Day 41)
n=26 participants at risk
Participants received 3 mg Orforglipron capsule once daily from Day 28 through Day 41.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Schwannoma
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/21 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.3%
1/19 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
Other adverse events
| Measure |
Cohort 1: 6 mg Orforglipron Capsule QD (Day 42 to Day 55)
n=26 participants at risk
Participants received 6 mg Orforglipron capsule once daily from Day 42 through Day 55.
|
Cohort 1: 12 mg Orforglipron Capsule QD (Day 56 to Day 69)
n=26 participants at risk
Participants received 12 mg Orforglipron capsule once daily from Day 56 through Day 69.
|
Cohort 1: 24 mg Orforglipron Capsule QD (Day 70 to Day 83)
n=26 participants at risk
Participants received 24 mg Orforglipron capsule once daily from Day 70 through Day 83.
|
Cohort 1: 36 mg Orforglipron Capsule QD (Day 84 to Day 97)
n=26 participants at risk
Participants received 36 mg Orforglipron capsule once daily from Day 84 through Day 97.
|
Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 98)
n=22 participants at risk
Participants received simultaneous dosing of 20 mg simvastatin and 36 mg Orforglipron orally on Day 98.
|
Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 0.25 mg Digoxin (Day 99)
n=22 participants at risk
Participants received simultaneous dosing of 0.25 mg digoxin and 36 mg Orforglipron orally on Day 99.
|
Cohort 1: 36 mg Orforglipron Capsule QD (Day 100 to Day 103)
n=22 participants at risk
Participants received 36 mg Orforglipron capsule once daily from Day 100 through Day 103.
|
Cohort 1: Staggered 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 104)
n=22 participants at risk
Participants received staggered dosing of 36 mg Orforglipron followed by 20 mg Simvastatin orally on Day 104.
|
Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 20 mg Rosuvastatin (Day 105)
n=22 participants at risk
Participants received simultaneous dosing of 20 mg rosuvastatin and 36 mg Orforglipron orally on Day 105.
|
Cohort 1: 36 mg Orforglipron Capsule (Day 106)
n=22 participants at risk
Participants received 36 mg Orforglipron orally on Day 106.
|
Cohort 1: Staggered 36 mg Orforglipron Capsule + 1000 mg Acetaminophen (Day 107)
n=22 participants at risk
Participants received staggered dosing of 36 mg Orforglipron capsule followed by 1000 mg acetaminophen orally on Day 107.
|
Cohort 1: 36 mg Orforglipron Capsule (Day 108)
n=22 participants at risk
Participants received 36 mg Orforglipron orally on Day 108.
|
Cohort 1: Simultaneous 36 mg Orforglipron Capsule + 0.2 mg Midazolam (Day 109)
n=21 participants at risk
Participants received simultaneous dosing of 0.2 mg midazolam and 36 mg Orforglipron orally on Day 109.
|
Cohort 1: 36 mg Orforglipron Capsule (Day 110)
n=22 participants at risk
Participants received 36 mg Orforglipron orally on Day 110.
|
Cohort 1: Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin (Day 111)
n=22 participants at risk
Participants received simultaneous dosing of 20 mg simvastatin and 20 mg Orforglipron orally on Day 111.
|
Cohort 2: 20 mg Simvastatin Alone (Day 1)
n=20 participants at risk
Participants received single dose of 20 mg simvastatin alone orally on Day 1.
|
Cohort 2: 0.25 mg Digoxin Alone (Day 2)
n=20 participants at risk
Participants received 0.25 mg digoxin alone on Day 2.
|
Cohort 2: Simultaneous 20 mg Simvastatin + 600 mg Sodium Bicarbonate (Day 7)
n=20 participants at risk
Participants received simultaneous dosing of 20 mg simvastatin and 600 mg sodium bicarbonate orally on Day 7.
|
Cohort 2: 1 mg Orforglipron Capsule QD (Day 9 to Day 22)
n=20 participants at risk
Participants received 1 mg Orforglipron capsule once daily from Day 9 through Day 22.
|
Cohort 2: 3 mg Orforglipron Capsule QD (Day 23 to Day 36)
n=20 participants at risk
Participants received 3 mg Orforglipron capsule once daily from Day 23 through Day 36.
|
Cohort 2: 6 mg Orforglipron Capsule QD (Day 37 to Day 50)
n=19 participants at risk
Participants received 6 mg Orforglipron capsule once daily from Day 37 through Day 50.
|
Cohort 2: 12 mg Orforglipron Capsule QD (Day 51 to Day 64)
n=19 participants at risk
Participants received 12 mg Orforglipron capsule once daily from Day 51 through Day 64.
|
Cohort 2: 24 mg Orforglipron Capsule QD (Day 65 to Day 78)
n=18 participants at risk
Participants received 24 mg Orforglipron capsule once daily from Day 65 through Day 78.
|
Cohort 2: 36 mg Orforglipron Capsule QD (Day 79 to Day 92)
n=18 participants at risk
Participants received 36 mg Orforglipron capsule once daily from Day79 through Day 92.
|
Cohort 2: Simultaneous 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 93)
n=16 participants at risk
Participants received simultaneous dosing of 20 mg simvastatin and 36 mg Orforglipron orally on Day 93.
|
Cohort 2: Simultaneous 36 mg Orforglipron Capsule + 0.25 mg Digoxin (Day 94)
n=16 participants at risk
Participants received simultaneous dosing of 0.25 mg digoxin and 36 mg Orforglipron orally on Day 94.
|
Cohort 2: 36 mg Orforglipron Capsule QD (Day 95 to Day 98)
n=16 participants at risk
Participants received 36 mg Orforglipron capsule once daily from Day 95 through Day 98.
|
Cohort 2: Staggered 36 mg Orforglipron Capsule + 20 mg Simvastatin (Day 99)
n=16 participants at risk
Participants received staggered dosing of 36 mg Orforglipron followed by 20 mg Simvastatin orally on Day 99.
|
Cohort 2: 36 mg Orforglipron Capsule (Day 100)
n=16 participants at risk
Participants received 36 mg Orforglipron capsule orally on Day 100.
|
Cohort 2: Simultaneous 20 mg Orforglipron Tablet + 20 mg Simvastatin (Day 101)
n=16 participants at risk
Participants received simultaneous dosing of 20 mg simvastatin and 20 mg Orforglipron orally on Day 101.
|
Cohort 1: 20 mg Simvastatin Alone (Day 1)
n=30 participants at risk
Participants received single dose of 20 mg simvastatin alone orally on Day 1.
|
Cohort 1: 0.25 mg Digoxin Alone (Day 2)
n=30 participants at risk
Participants received 0.25 mg digoxin alone on Day 2.
|
Cohort 1: 20 mg Simvastatin + 600 mg Sodium Bicarbonate (Day 7)
n=28 participants at risk
Participants received simultaneous dosing of 20 mg simvastatin and 600 mg sodium bicarbonate orally on Day 7.
|
Cohort 1: 20 mg Rosuvastatin Alone (Day 8)
n=28 participants at risk
Participants received single dose of 20 mg rosuvastatin alone orally on Day 8.
|
Cohort 1: 1000 mg Acetaminophen Alone (Day 10)
n=27 participants at risk
Participants received single dose of 1000 mg acetaminophen alone orally on Day 10.
|
Cohort 1: 0.2 mg Midazolam Alone (Day 12)
n=27 participants at risk
Participants received single dose of 0.2 mg midazolam alone orally on Day 12.
|
Cohort 1: Staggered 1 mg Orforglipron Capsule + 1000 mg Acetaminophen (Day 14)
n=27 participants at risk
Participants received staggered dosing of 1 mg single dose of Orforglipron followed by 1000 mg acetaminophen orally on Day 14.
|
Cohort 1: 1 mg Orforglipron Capsule QD (Day 15 to Day 27)
n=27 participants at risk
Participants received 1 mg Orforglipron capsule once daily from Day 15 through Day 27.
|
Cohort 1: 3 mg Orforglipron Capsule QD (Day 28 to Day 41)
n=26 participants at risk
Participants received 3 mg Orforglipron capsule once daily from Day 28 through Day 41.
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
3.8%
1/26 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
7.7%
2/26 • Number of events 2 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/21 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
10.0%
2/20 • Number of events 2 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
4.5%
1/22 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/21 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
6.2%
1/16 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
23.1%
6/26 • Number of events 6 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
4.5%
1/22 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/21 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.0%
1/20 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.0%
1/20 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.3%
1/19 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.3%
1/19 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.6%
1/18 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
22.2%
4/18 • Number of events 4 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
6.2%
1/16 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
6.2%
1/16 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
|
Gastrointestinal disorders
Diarrhoea
|
3.8%
1/26 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
3.8%
1/26 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
3.8%
1/26 • Number of events 2 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
4.5%
1/22 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
4.5%
1/22 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/21 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.0%
1/20 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.0%
1/20 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.3%
1/19 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.6%
1/18 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.6%
1/18 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
3.8%
1/26 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
|
Gastrointestinal disorders
Dyspepsia
|
7.7%
2/26 • Number of events 2 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/21 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.3%
1/19 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.3%
1/19 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
|
Gastrointestinal disorders
Eructation
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/21 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
15.0%
3/20 • Number of events 3 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.0%
1/20 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
10.5%
2/19 • Number of events 2 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.6%
1/18 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
|
Gastrointestinal disorders
Nausea
|
7.7%
2/26 • Number of events 2 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
11.5%
3/26 • Number of events 3 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
9.1%
2/22 • Number of events 2 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
4.5%
1/22 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/21 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.0%
1/20 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
10.0%
2/20 • Number of events 2 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
10.0%
2/20 • Number of events 2 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.3%
1/19 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.3%
1/19 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.6%
1/18 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
3.7%
1/27 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
3.8%
1/26 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
|
Gastrointestinal disorders
Vomiting
|
3.8%
1/26 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
3.8%
1/26 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
7.7%
2/26 • Number of events 2 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
4.5%
1/22 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/21 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.0%
1/20 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.3%
1/19 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.6%
1/18 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
|
General disorders
Fatigue
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
3.8%
1/26 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/21 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
15.8%
3/19 • Number of events 3 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.6%
1/18 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
3.7%
1/27 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
3.8%
1/26 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
|
General disorders
Pyrexia
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
3.8%
1/26 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/21 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.0%
1/20 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.3%
1/19 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.6%
1/18 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
|
Infections and infestations
Influenza
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/21 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.3%
1/19 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
|
Infections and infestations
Viral infection
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/21 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.6%
1/18 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
6.2%
1/16 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
|
Infections and infestations
Viral rhinitis
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/21 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.6%
1/18 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
|
Injury, poisoning and procedural complications
Medication error
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/21 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.0%
1/20 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.6%
1/18 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
7.4%
2/27 • Number of events 2 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
3.8%
1/26 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
3.8%
1/26 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/21 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
9.1%
2/22 • Number of events 2 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.0%
1/20 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
12.5%
2/16 • Number of events 2 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
|
Investigations
Aspartate aminotransferase increased
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
3.8%
1/26 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
3.8%
1/26 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/21 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
9.1%
2/22 • Number of events 2 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.0%
1/20 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
12.5%
2/16 • Number of events 2 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
4.5%
1/22 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/21 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
10.0%
2/20 • Number of events 2 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.3%
1/19 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
4.5%
1/22 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/21 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.3%
1/19 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/21 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.3%
1/19 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
4.5%
1/22 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
4.8%
1/21 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.0%
1/20 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.0%
1/20 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.3%
1/19 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.3%
1/19 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
|
Nervous system disorders
Headache
|
3.8%
1/26 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
3.8%
1/26 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
7.7%
2/26 • Number of events 2 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
4.5%
1/22 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
4.5%
1/22 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
4.8%
1/21 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
10.0%
2/20 • Number of events 2 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
10.5%
2/19 • Number of events 2 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.3%
1/19 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
6.2%
1/16 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
6.7%
2/30 • Number of events 2 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
3.7%
1/27 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/21 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
6.2%
1/16 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
|
Psychiatric disorders
Euphoric mood
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/21 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.0%
1/20 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.6%
1/18 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/21 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.6%
1/18 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
|
Psychiatric disorders
Restlessness
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/21 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.6%
1/18 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
|
Reproductive system and breast disorders
Dysmenorrhoea
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
3.8%
1/26 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/21 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
6.2%
1/16 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
3.7%
1/27 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/21 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.3%
1/19 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/21 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/22 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/20 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/19 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/18 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
5.6%
1/18 • Number of events 1 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/16 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/30 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/28 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/27 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
0.00%
0/26 • Cohort 1: Baseline up to end of follow-up (up to 129 days); Cohort 2: Baseline up to end of follow-up (up to 119 days)
All participants who received at least 1 dose of study drug (Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, and Midazolam). Participants were analyzed according to the treatment regimen they received.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: GT60